Compass Therapeutics Inc. (NASDAQ: CMPX) announced it will present phase 1 clinical data for CTX-8371 at the 2026 American Society ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE